Can Zydus saroglitazar compete with Iqirvo and Livdelzi in the US PBC market?
Zydus saroglitazar shows 60.7% US biochemical response in PBC as its November 27 FDA decision approaches. Examine the Phase 3 evidence.
Pharma & Biotech
Pharma & Biotech
What does RC220 dose escalation mean for Racura Oncology’s cancer drug pipeline?
Racura Oncology clears RC220 dose escalation to 100 mg/m² in its lung cancer trial. Examine the safety findings and next clinical milestones.
Medical Devices & Diagnostics
How the da Vinci SP system is changing selected breast cancer surgery workflows
MedStar Georgetown combines four breast procedures through one 4-centimeter robotic incision. Examine safety, sensation and clinical evidence.
Medical Devices & Diagnostics
An implant for severe asthma? Spiro Medical begins testing spinal nerve stimulation beyond drugs
Spiro Medical implants its first PULSAR asthma patient as a 30-person study tests spinal nerve stimulation for severe, uncontrolled asthma.
Pharma & Biotech
Can Lunit’s AI pathology partnership accelerate cancer biomarker discovery?
Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.
Pharma & Biotech
Can Chipscreen’s AI-discovered CS43158 overcome leukemia drug resistance? China clears human trials
Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.
Pharma & Biotech
Amphista Therapeutics begins first human trial of AMX-883 BRD9 degrader in acute myeloid leukemia
Amphista begins its 54-patient AMX-883 Phase 1 trial in AML and high-risk MDS. Examine the novel BRD9 mechanism, safety tests and next milestones.
Pharma & Biotech
I2Pure’s iodine formulations kill over 99.9% of major pathogens in seconds, but can hospitals use them?
I2Pure molecular iodine kills major drug-resistant pathogens within seconds in lab tests. Examine efficacy, staining and hospital adoption barriers.
Pharma & Biotech
Keenova’s TERLIVAZ shows kidney response in transplant-ineligible patients as new CONFIRM analysis emerges
Keenova's TERLIVAZ analysis examines kidney recovery in transplant-ineligible HRS-AKI patients as respiratory safety and survival remain key concerns.
Pharma & Biotech
Tortugas Neuroscience reports positive Phase 2b results for schizophrenia treatment
Obuprazine met the primary endpoint across three dose groups in a 363-patient Phase 2b schizophrenia study, with the strongest dose producing a 16.7-point placebo-adjusted PANSS improvement. Early symptom responses and low discontinuation rates support further development, but longer-term safety and comparative efficacy remain unproven.